BioMarin Acquires Alesta Therapeutics for $275 Million in Deal with Potential Additional Payments
BioMarin Pharmaceutical has agreed to acquire Alesta Therapeutics for an upfront payment of $275 million, with the potential for up to an additional $215 million based on development milestones. The deal grants BioMarin access to ALE1, Alesta's oral treatment candidate for hypophosphatasia (HPP), a rare genetic bone disease currently in early clinical trials. This acquisition strengthens BioMarin’s portfolio focused on rare skeletal conditions and marks its third major move in the rare disease space within the past year. The company aims to expand into larger patient populations with innovative, clinical-stage assets like ALE1, which could become the first oral treatment for HPP if successful.
Tickers: $BMRN